Business Wire

LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology

BALLERUP, Denmark & DUBLIN--(BUSINESS WIRE)--#partnership--LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and...

NuStar to Participate in the Seventh Annual Mizuho Energy Summit

SAN ANTONIO--(BUSINESS WIRE)--NuStar Energy L.P. (NYSE: NS) announced today that members of management will participate in meetings with members of the investment community at the Seventh Annual Mizuho Energy Summit on Monday, March 13, 2023 and Tuesday, March 14,...

Magellan Aerospace Corporation Announces Financial Results

TORONTO--(BUSINESS WIRE)--Magellan Aerospace Corporation (“Magellan” or the “Corporation”) released its financial results for the fourth quarter of 2022. All amounts are expressed in Canadian dollars unless otherwise indicated. The results are summarized as follows:     Three month period ended December 31 Twelve month...

Capitolis Announces Further Progress in the Expansion of its Capital Marketplace Business

On the heels of its security-based swap dealer registration, Capitolis’ subsidiary has submitted an application to become a registered broker-dealer in anticipation of new products NEW YORK--(BUSINESS WIRE)--Capitolis, the technology company reimagining financial markets, announced that its subsidiary, Capitolis Global...

Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic...

– Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option in patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy – TOKYO &...

Inmarsat: Greener Flights Coming to Italy Soon as ITA Airways to Join Iris Air Traffic Modernisation Programme

The Italian flag carrier will be the first full service airline in Europe to join the ground-breaking programme by Inmarsat and European Space Agency (ESA) LONDON--(BUSINESS WIRE)--Digitally-connected flights to and from Italy will be available from this summer, as ITA...

Develop Diverse: Job Adverts Written by ChatGPT Nearly Twice as Biased Than Those From Humans

Job adverts written by ChatGPT are 40% more biased than those written by humans. It’s particularly biased against neurodivergent people, people with physical disabilities and people from disadvantaged ethnic groups. COPENHAGEN--(BUSINESS WIRE)--New research suggests we should use ChatGPT with caution, especially...

QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

QIAGEN to develop PCR test to detect isocitrate dehydrogenase-1 (IDH1) mutations in AML patients to be used with Servier’s marketed and investigational targeted treatment Test for blood and bone marrow samples to run on QIAGEN Rotor-Gene Q device QIAGEN now working...

Nidec’s Disaster Relief and Recovery Assistance for Turkey-Syria Earthquake

KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (“Nidec”) would like to extend its deepest sympathy and condolences to the people of Turkey and Syria affected by the devastating earthquake that struck the region on February 6th. As...

GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology

Pooled analysis of safety data from 5 clinical studies in 189 patients constituting the largest ever ND4-LHON cohort treated with gene therapy Confirmation of the long-term safety profile of intravitreal injections of LUMEVOQ® with data covering a 5-year period following...

Latest News

Pembina Pipeline Corporation Announces Conversion Results for Series 5 Preferred Shares

CALGARY, Alberta--(BUSINESS WIRE)--Pembina Pipeline Corporation ("Pembina") (TSX: PPL; NYSE: PBA) announced today that none of Pembina's Cumulative Redeemable Rate...